Topoisomerase 1 inhibitors have been shown to be effective in cancer therapy of HR-deficient, Schlafen 11-positive cells in association with Olaparib, for the treatment of BRCA1-, BRCA2-, and PALB2-deficient cells [92]. Here, BRCA2 is linked to cancer.